Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Izhstal reported for 6 months of 2024 by IFRS

8/29/24 IGST

UAC reports for 6 months of 2024 by IFRS

8/29/24 UNAC

Korshunovsky GOK reported for 6 months of 2024 by IFRS

8/29/24 KOGK

Chizhik opened a distribution center in the Moscow region

8/29/24 X5

VK has moved all video content to a single Opecloud repository

8/29/24 VKCO

Etalon reported for 6 months of 2024

8/29/24 ETLN

Mostotrest reported for 6 months of 2024 by IFRS

8/29/24 MSTT

En+ Group reported for 6 months of 2024 by IFRS

8/29/24 ENPG

AMZ reported for 6 months of 2024 by IFRS

8/29/24 AMEZ

Board of Directors of MD Medical Group Investments recommended dividends

8/29/24 MDMG